PRESS RELEASE published on 11/03/2023 at 18:05, 2 years 8 months ago Secarna Pharmaceuticals presents data at SITC demonstrating the potential of antisense oligonucleotides in targeting NRP1
PRESS RELEASE published on 10/25/2023 at 15:00, 2 years 9 months ago Secarna Pharmaceuticals presents data at OTS showcasing unique characteristics and factors with a role in the activity and side effect profile of LNA-modified ASOs
PRESS RELEASE published on 10/17/2023 at 14:00, 2 years 9 months ago Secarna Pharmaceuticals to present two posters showcasing the innovation potential of the LNAplus platform at the 19th Annual Meeting of the Oligonucleotide Therapeutic Society
PRESS RELEASE published on 07/06/2023 at 14:00, 3 years ago Secarna Pharmaceuticals publishes new preclinical data in The Journal of Immunology demonstrating potent therapeutic activity of LNAplus™ ASO targeting NLRP3 in debilitating autoinflammatory diseases
PRESS RELEASE published on 06/05/2023 at 14:00, 3 years 1 month ago Secarna Pharmaceuticals announces publication of new preclinical data showing durable antitumor activity of LNAplus™-based ASOs that both stimulate the innate immune system and suppress PD-L1 expressi
PRESS RELEASE published on 03/27/2023 at 16:04, 3 years 4 months ago Secarna Pharmaceuticals and SciNeuro Pharmaceuticals enter into research and option agreement in the field of CNS diseases
Published on 07/30/2026 at 04:10, 2 hours 45 minutes ago Pathfinder Ventures Announces Appointment of Mark Roseborough as Chief Executive Officer
Published on 07/30/2026 at 01:50, 5 hours 5 minutes ago Further Assays Infill Tunkillia Pit Extension Targets
Published on 07/30/2026 at 00:50, 6 hours 5 minutes ago Aton Announces Strategic Cooperation Relationship and Board Nominee
Published on 07/30/2026 at 00:00, 6 hours 55 minutes ago American Hotel Income Properties REIT LP to Host Second Quarter 2026 Results Conference Call on August 6, 2026
Published on 07/29/2026 at 23:01, 7 hours 54 minutes ago Blueberries Medical Announces C$1.1 Million Non-Brokered Private Placement
Published on 07/30/2026 at 06:30, 25 minutes ago Avolta delivered a resilient performance in H1 2026 despite strong geopolitical headwinds
Published on 07/30/2026 at 06:00, 55 minutes ago Recovery in demand hampered by political uncertainties
Published on 07/29/2026 at 21:45, 9 hours 10 minutes ago Piramal Pharma Limited Announces Results for Q1 FY27
Published on 07/29/2026 at 21:12, 9 hours 43 minutes ago Interim individual report for the period ending on 30.06.2026
Published on 07/29/2026 at 23:00, 7 hours 55 minutes ago BIOPHYTIS ANNOUNCES THE AUDITING OF ITS 2025 FINANCIAL STATEMENTS AND THE RESUMPTION OF TRADING IN ITS STOCK
Published on 07/29/2026 at 18:40, 12 hours 15 minutes ago Aéroports de Paris SA - Availability of the 2026 financial interim report
Published on 07/29/2026 at 18:30, 12 hours 25 minutes ago Aéroports de Paris SA - Groupe ADP 2027-2034 Economic Regulation Agreement (ERA) project
Published on 07/29/2026 at 18:29, 12 hours 26 minutes ago Aéroports de Paris SA - 2026 Half-year results
Published on 07/29/2026 at 17:54, 13 hours 1 minute ago Availability of the half-year financial report for 2026
